Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 06, 2024 08:57 ET | Source: SciSparc Ltd

SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

SciSparc has been collaborating with Clearmind Medicine to create effective treatments for obesity and metabolic syndrome by combining SciSparc’s Palmitoylethanolamide (PEA) with Clearmind’s MEAI ...
July 22, 2024 08:20 ET | Source: SciSparc Ltd

SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer

The discovery was demonstrated by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors TEL AVIV, Israel, July 22, 2024 (GLOBE NEWSWIRE) -- ...
July 17, 2024 07:07 ET | Source: SciSparc Ltd

SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

SciSparc will receive additional payments and execution fees if certain milestones are met TEL AVIV, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or...
July 16, 2024 11:55 ET | Source: SciSparc Ltd

SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and...
July 16, 2024 06:03 ET | Source: SciSparc Ltd

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
July 08, 2024 08:30 ET | Source: SciSparc Ltd

SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company

According to the agreement, SciSparc’s pharmaceuticals assets are valued at approximately $11.6 million TEL AVIV, Israel, July 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC)...
May 31, 2024 07:17 ET | Source: SciSparc Ltd

SciSparc Secures Strategic Advantage with Grant of European Patent

TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
April 11, 2024 08:15 ET | Source: SciSparc Ltd

SciSparc to Acquire AutoMax

TEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
March 27, 2024 08:55 ET | Source: SciSparc Ltd

SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression

TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
March 21, 2024 08:58 ET | Source: SciSparc Ltd

SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research

MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC)...